左卡尼汀联合曲美他嗪治疗扩张型心肌病的疗效及对患者心功能的影响

doi:10.3969/j.issn.1671-7171.2024.07.020

摘要
图/表
参考文献
相关文章 (15)

全文: PDF (1213 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要【目的】探讨左卡尼汀联合曲美他嗪治疗扩张型心肌病(DCM)的临床疗效及对患者心功能的影响。【方法】选取2022年1月至2023年2月本院收治的102例DCM患者,根据随机数字表法将其分为对照组(在常规用药的基础上给予曲美他嗪治疗)和观察组(在对照组的基础上给予左卡尼汀治疗),每组51例。比较两组疗效,治疗前与治疗后心功能指标[心脏指数(CI)、左室射血分数(LVEF)、左室舒张末期内径(LVEDD)]、实验室指标[Periostin蛋白、转化生长因子-β1(TGF-β1)、可溶性生长刺激表达基因2蛋白(sST2)、心肌肌钙蛋白T(cTnT)、肌酸激酶同工酶(CK-MB)、肌红蛋白(Mb)]。【结果】观察组总有效率显著高于对照组,差异有统计学意义(P<0.05)。治疗后,两组CI、LVEF均高于治疗前,且观察组高于对照组;两组LVEDD低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。治疗后,两组cTnT、CK-MB、Mb、Periostin蛋白、TGF-β1、sST2均低于治疗前,且观察组低于对照组,差异有统计学意义(P<0.05)。【结论】左卡尼汀联合曲美他嗪治疗DCM患者效果显著,可改善患者心功能,抑制心室重构。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	文亚晓
	杨立慧
	杨志阁

关键词 ：心肌病, 扩张型/药物疗法, 乙酰肉碱/治疗应用, 曲美他嗪/治疗应用, 心脏功能试验

Abstract：【Objective】To investigate the clinical efficacy of levocarnitine combined with trimetazidine in the treatment of dilated cardiomyopathy (DCM) and its impact on patients' cardiac function. 【Methods】A total of 102 DCM patients admitted to our hospital from January 2022 to February 2023 were selected and randomly divided into a control group (treated with trimetazidine in addition to conventional medication) and an observation group (treated with levocarnitine in addition to the control group) using a random number table method, with 51 patients in each group. Two groups of therapeutic effects were compared, including pre-and post-treatment cardiac function indicators such as cardiac index (CI), left ventricular ejection fraction (LVEF), left ventricular end diastolic diameter (LVEDD), laboratory indicators such as periostin protein, transforming growth factor-β1 (TGF-β1), soluble growth stimulating gene 2 protein (sST2), cardiac troponin T (cTnT), creatine kinase isoenzyme (CK-MB), and myoglobin (Mb). 【Results】The total effective rate of the observation group was significantly higher than that of the control group, and the difference was statistically significant (P<0.05). After treatment, the CI and LVEF of both groups were higher than before treatment, and the observation group was higher than the control group; The LVEDD of both groups was lower than before treatment, and the observation group was lower than the control group, with a statistically significant difference (P<0.05). After treatment, cTnT, CK-MB, Mb, Periostin protein, TGF-β1, and sST2 in both groups were lower than before treatment, and the observation group was lower than the control group, with statistical significance (P<0.05). 【Conclusion】The combination of levocarnitine and trimetazidine is effective in treating DCM patients, improving their cardiac function and inhibiting ventricular remodeling.

Key words： Cardiomyopathy, Dilated/DT Acetylcarnitine/TU Trimetazidine/TU Heart Function Tests

收稿日期: 2023-08-31

中图分类号:

R542.2

引用本文:

文亚晓, 杨立慧, 杨志阁. 左卡尼汀联合曲美他嗪治疗扩张型心肌病的疗效及对患者心功能的影响[J]. 医学临床研究, 2024, 41(7): 1031-1033.
WEN Yaxiao, YANG Lihui, YANG Zhige. The Efficacy of Levocarnitine Combined with Trimetazidine in the Treatment of Dilated Cardiomyopathy and its Impact on Patients' Cardiac Function. JOURNAL OF CLINICAL RESEARCH, 2024, 41(7): 1031-1033.

链接本文:

http://journal07.magtech.org.cn/yxlcyj/CN/10.3969/j.issn.1671-7171.2024.07.020 或 http://journal07.magtech.org.cn/yxlcyj/CN/Y2024/V41/I7/1031